New GERD Symptoms After Starting a GLP-1 Receptor Agonist
New reflux symptoms that began within weeks of starting a GLP-1 receptor agonist raise a real and increasingly common question, given how widely this drug class is now used: treat the reflux directly, or address the delayed gastric emptying actually driving it.
Denise A., 51, started semaglutide four months ago for type 2 diabetes management after her endocrinologist titrated her up from metformin alone, and has genuinely welcomed the fourteen pounds she's lost since — enough that she's started walking her neighborhood loop again most evenings, something she'd stopped doing two years ago. About six weeks after reaching her current maintenance dose, she began having heartburn most nights, along with a new sensation of food “sitting” heavily after meals that hadn't been part of her experience before. She has no personal or family history of reflux disease, no prior GI complaints of any kind, and her A1c has improved meaningfully alongside the weight loss, which makes her reluctant to consider stopping a drug that's otherwise working exactly as intended.
GLP-1 receptor agonists slow gastric emptying as a core, dose-dependent part of their mechanism — part of why they reduce appetite and improve postprandial glucose, and also a contributor to reflux symptoms real enough that a 2025 systematic review and meta-analysis of 55 placebo-controlled trials found GLP-1 receptor agonists roughly doubled the risk of GERD, an effect that showed up more strongly in trials using weight-loss-inducing, high-dose formulations like hers, particularly as doses are titrated upward. That mechanism matters for how her symptoms should actually be treated: unlike primary GERD, where acid suppression alone usually resolves things, her reflux may be substantially driven by food and gastric contents lingering longer than her stomach used to hold them, which a PPI addresses only partially — it reduces the acidity of what refluxes, not the fact that more material is available to reflux in the first place.
That delay is dose-dependent in a way that matters for her specifically: it is most pronounced during escalation and tends to partially attenuate somewhat with sustained use at a stable dose, which is part of why holding her next titration step, rather than reducing her current maintenance dose, is a reasonable middle path — it removes the specific trigger tied to her symptom onset without asking her to give up the metabolic benefit she's already achieved at her current dose.
Treating the reflux without giving up what's working
I want to name the mechanism plainly before we default straight to a PPI: GLP-1 receptor agonists slow gastric emptying as a real, dose-dependent part of how they work, and her symptoms started within six weeks of her last dose increase. That's not a coincidental new GERD diagnosis — that timeline points directly at the drug's own mechanism. I'd talk to her about holding the next planned titration step rather than treating this as unrelated.
I don't disagree with the mechanism. What I'd add is that a PPI trial is low-risk and reasonable to start now regardless of what happens with the titration decision — her A1c and weight outcomes have been genuinely strong, and she's told us directly she doesn't want to give that up. Starting acid suppression gives her real symptom relief while that separate conversation happens.
I'd push back gently on treating the titration-pace question as the whole answer, though: a PPI addresses the acidity of what refluxes, and even if we hold her dose steady, she may still have real, ongoing postprandial fullness a PPI alone won't touch — that's a genuinely separate symptom from the heartburn itself.
I'd do both together rather than sequentially. These aren't competing fixes for the same problem — a PPI treats the acid, and slowing the titration pace addresses the actual motility change driving the reflux in the first place. Starting the PPI now while the endocrinologist revisits the dose-escalation plan gives her relief without asking her to choose between symptom control and the diabetes outcomes she's genuinely proud of.
Agreed: PPI started today, semaglutide continued at current maintenance dose with the next planned titration step deferred, and a four-week follow-up to reassess both her reflux symptoms and her glycemic control on the held dose before revisiting whether to resume titration.